Comparative adverse event profiles of triplet therapy versus docetaxel-based therapy in patients with metastatic prostate cancer: a multicenter retrospective study by Fumihiko Urabe, Hirokazu Kagawa, Takafumi Yanagisawa, Hidetsugu Takahashi, Masaki Hashimoto, Shuhei Hara, Wataru Fukuokaya, Yu Imai, Kosuke Iwatani, Taro Igarashi, Mahito Atsuta, Kojiro Tashiro, Masaya Murakami, Shunsuke Tsuzuki, Brendan A. Yanada, Toshihiro Yamamoto, Kenichi Hata, Hiroki Yamada, Jun Miki, Takahiro Kimura

Get full text

Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis by Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, Tatsushi Kawada, Satoshi Katayama, Ekaterina Laukhtina, Pawel Rajwa, Fahad Quhal, Benjamin Pradere, Wataru Fukuokaya, Kosuke Iwatani, Renate Pichler, Jeremy Yuen-Chun Teoh, Marco Moschini, Wojciech Krajewski, Jun Miki, Shahrokh F. Shariat, Takahiro Kimura, European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)

Get full text

Eosinophils as a predictive marker of treatment-related adverse events in mRCC patients treated with first-line immune-checkpoint inhibitor combination therapy by Tatsushi Kawada, Satoshi Katayama, Takafumi Yanagisawa, Keiichiro Mori, Wataru Fukuokaya, Kazumasa Komura, Takuya Tsujino, Ryoichi Maenosono, Kiyoshi Takahara, Takuhisa Nukaya, Lan Inoki, Shingo Toyoda, Takeshi Hashimoto, Yosuke Hirasawa, Kohei Edamura, Tomoko Kobayashi, Kensuke Bekku, Shingo Nishimura, Takehiro Iwata, Takuya Sadahira, Yusuke Tominaga, Tomoaki Yamanoi, Kasumi Yoshinaga, Kazuma Tsuboi, Yasuyuki Kobayashi, Atsushi Takamoto, Kyohei Kurose, Takahiro Kimura, Haruhito Azuma, Ryoichi Shiroki, Kazutoshi Fujita, Yoshio Ohno, Motoo Araki, On behalf of JK-FOOT study group

Get full text